Lower is better with LIVDELZI

For people with primary biliary cholangitis (PBC), LIVDELZI is the first and only treatment shown to significantly reduce alkaline phosphatase (ALP) and PBC-related itch vs placebo.*

LIVDELZI is a prescription medicine used to treat PBC in combination with UDCA (also known as urso or ursodeoxycholic acid) in adults who have not responded well to UDCA, or used alone in patients unable to tolerate UDCA.

LIVDELZI is not recommended for use in people who have advanced liver disease (decompensated cirrhosis). Symptoms of advanced liver disease may include confusion; having fluid in the stomach area (abdomen); black, tarry, or bloody stools; coughing up or vomiting blood; or having vomit that looks like “coffee grounds”.

It is not known if taking LIVDELZI will improve your chance of survival or prevent liver decompensation.

It is not known if LIVDELZI is safe and effective in children.

See ALP and itch data
Resources for You

Start the conversation with your doctor to see if LIVDELZI could work for you.

Download a guide

Learn how to get started on LIVDELZI.

Financial Resources

Support Path® specialists can help you with:

  • Insurance information and coverage options

  • Co-pay Coupon Program for eligible patients

  • Assistance for the uninsured

Sign Up to Stay Informed

Get helpful information about LIVDELZI and PBC.

In a clinical study,
LIVDELZI improved measures of PBC

In participants taking LIVDELZI, about 6 out of 10 met the key study goal for PBC treatment by 12 months. The key study goal was:

  • ALP less than 1.67 x the upper limit of normal (ULN)

  • ALP decreased by at least 15% from start of study

  • Maintained normal bilirubin levels

LIVDELZI is the only PBC treatment that normalized ALP in 1 out of 4 participants by 12 months.
LIVDELZI is the only PBC treatment proven to significantly reduce itch by 6 months. In the clinical study, LIVDELZI:  
  • Showed rapid itch reduction as early as month 1

  • Reduced PBC itch by ~2x more than the placebo group (a mean change of -3.2 points on the Numerical Rating Scale [NRS]§ by 6 months with LIVDELZI vs -1.7 points in the placebo group)

Ask your doctor if LIVDELZI could work for you.

In this clinical study of 193 people with PBC, LIVDELZI was given either with urso or alone. The results were compared with the placebo group, which included participants who took placebo (a treatment that does not contain medicine) with or without urso. In this study, 128 participants took LIVDELZI and 65 participants were in the placebo group.

In the clinical study, 2 out of 10 participants in the placebo group met the key study goal for PBC treatment compared to about 6 out of 10 participants taking LIVDELZI.

ULN refers to the high end of the normal range of a lab results value.

§The NRS is a scale of 0-10 that measures itch severity, with 10 being the worst possible itch.

Participants evaluated in the study began the trial with NRS scores of ≥4.